Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases.

Antoni B. Chan | I. Bruce | C. Gordon | P. Doherty | B. Dasgupta | B. Griffiths | N. Peek | K. Payne | D. Morris | T. Vyse | V. Farewell | R. Haigh | M. Lunt | N. Geifman | M. Wittmann | E. Vital | S. Haque | L. Teh | P. Emery | R. Stratton | Patrick Gordon | M. Batley | Y. Ahmad | P. Lanyon | A. Midgley | E. O'Riordan | D. Jayne | C. Hedrich | David Hutchinson | Michael Ehrenstein | E. Vermaak | Lauren Y. Hewitt | L. Mccann | Neil McHugh | Adrian T. Farrell | N. Erb | Richard A. Watts | N. Gullick | Alyssa C. Gilmore | M. Botto | N. Azadbakht | S. Bartram | S. Gavan | A. Zoma | J. Gritzfeld | Z. McLaren | J. Reynolds | A. Kaul | D. Mewar | R. Mediwake | S. Hamdulay | S. Skeoch | L. Gompels | C. Rhys-Dillon | F. Carlucci | D. Pyne | L. Su | M. Gayed | D. De Lord | M. Akil | H. Youssef | C. Edwards | J. Prattley | D. D’Cruz | D. Isenberg | S. Shaffu | J. Dunnage | M. Parvaz | E. Lightstone | T. Sheeran | I. Bruce | G. Armitt | Angela Papazian | Helen Le Sueur | Carmen Farrelly | Clare M Richardson | Zunnaira Shabbir | Lauren Hewitt | Stephen Young | M. Pickering | M. Beresford | Jane Batchelor | Elaine Holland | Pauline Upsall | Anurag Bharadwaj | Deepti Kapur | Prof Chee-Seng Yee | A. Yusuf | J. Wijeyekoon | Cee Yi Yong | R. Jeffery | Fouz Rahmeh | Steven Young Min | Benedict Rhodes | J. Marks | Maria Regan | Harsha Gunwardena | M. Mahindrakar | Bhrigu Raj Sood | Joanna C Robson | Jon King | S. Knights | Carmen Farrelly | Clare M. Richardson | L. McCann | P. Gordon | C. Farrelly | Christopher J. Edwards | S. Young Min | Li Su | Denise De Lord

[1]  Asher Mullard.  FDA approves AstraZeneca’s anifrolumab for lupus , 2021, Nature Reviews Drug Discovery.

[2]  E. Svenungsson,et al.  Global epidemiology of systemic lupus erythematosus , 2021, Nature Reviews Rheumatology.

[3]  I. Bruce,et al.  What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials , 2021, Arthritis & rheumatology.

[4]  D. Isenberg,et al.  Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage , 2020, Arthritis care & research.

[5]  I. Bruce,et al.  Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations , 2020, Lupus science & medicine.

[6]  M. Herdman,et al.  Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines , 2020, European Journal of Health Economics.

[7]  Systemic Lupus Erythematosus Disease Activity Index , 2020, Definitions.

[8]  C. Gordon,et al.  2019 update of the EULAR recommendations for the management of systemic lupus erythematosus , 2019, Annals of the rheumatic diseases.

[9]  I. Bruce,et al.  Current challenges in the development of new treatments for lupus , 2019, Annals of the rheumatic diseases.

[10]  J. Gottenberg,et al.  The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. , 2018, Autoimmunity reviews.

[11]  S. Schüler.  Methods for planning and analyzing clinical trials with composite endpoints , 2018 .

[12]  S. Simoens,et al.  Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  Coady Wing,et al.  Designing Difference in Difference Studies: Best Practices for Public Health Policy Research. , 2018, Annual review of public health.

[14]  D. Gladman,et al.  Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments , 2017, Lupus Science & Medicine.

[15]  Andrea Manca,et al.  Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  Guideline on multiplicity issues in clinical trials 4 Draft 5 Draft agreed , 2017 .

[17]  D. Isenberg,et al.  Off-label use of rituximab for systemic lupus erythematosus in Europe , 2016, Lupus Science & Medicine.

[18]  M. Doherty,et al.  The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012 , 2014, Annals of the rheumatic diseases.

[19]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[20]  D. Gladman,et al.  Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials , 2014, Lupus Science & Medicine.

[21]  C. Gordon,et al.  Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study , 2013, Annals of the rheumatic diseases.

[22]  M. Joore,et al.  How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  Alan Brennan,et al.  Modelling in Health Economic Evaluation , 2000, PharmacoEconomics.

[24]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[25]  Lisa M. Schwartz,et al.  Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review , 2010, BMJ : British Medical Journal.

[26]  F. Wolfe,et al.  EQ-5D and SF-36 Quality of Life Measures in Systemic Lupus Erythematosus: Comparisons with Rheumatoid Arthritis, Noninflammatory Rheumatic Disorders, and Fibromyalgia , 2010, The Journal of Rheumatology.

[27]  M. Petri,et al.  Novel evidence-based systemic lupus erythematosus responder index. , 2009, Arthritis and rheumatism.

[28]  I. Bruce,et al.  The BILAG-2004 index is sensitive to change for assessment of SLE disease activity , 2009, Rheumatology.

[29]  G. Guyatt,et al.  Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. , 2007, Journal of clinical epidemiology.

[30]  Kenneth G. C. Smith,et al.  Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. , 2006, Arthritis and rheumatism.

[31]  M. Sculpher,et al.  Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. , 2005, Health economics.

[32]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[33]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[34]  A. Brennan,et al.  Modelling in health economic evaluation. What is its place? What is its value? , 2000, PharmacoEconomics.

[35]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[36]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[37]  M. Petri,et al.  Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. , 1991, Arthritis and rheumatism.

[38]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[39]  Endpoints used for Relative Effectiveness Assessment Composite endpoints , 2022 .